STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations

“They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.

Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.

The psychedelics field is getting what it has long wanted. Now it has to step up.

Ambiguous loss is at the heart of the dementia illness experience.